Acquired Company
Novartis completed the acquisition of Tourmaline Bio, Inc., and Tourmaline became an indirect wholly owned subsidiary of Novartis.
Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions, with a particular emphasis on autoimmune disorders and oncology. Leveraging its proprietary technology platform, the company has established a robust pipeline of innovative therapies designed to meet critical unmet medical needs in the realm of precision medicine. With a strong commitment to scientific excellence and strategic collaborations, Tourmaline Bio is well-positioned to capitalize on transformative growth opportunities within the biopharmaceutical sector, making it an attractive investment prospect for institutional investors. Show more
27 WEST 24TH STREET, NEW YORK, NY, UNITED STATES, 10010, New York, NY, 10010, USA
Market Cap
1.233B
52 Wk Range
$19.75 - $48.27
Previous Close
$47.98
Open
$47.98
Volume
N/A
Day Range
$47.98 - $47.98
Enterprise Value
990.8M
Cash
31.42M
Avg Qtr Burn
-20.26M
Insider Ownership
14.62%
Institutional Own.
89.13%
Qtr Updated
06/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Pacibekitug (TOUR006) Details Thyroid Eye Disease | Phase 2b Update | |
Pacibekitug (TOUR006) Details Atherosclerotic cardiovascular disease (ASCVD) | Phase 2 Update | |
FCR001 Details Scleroderma | Failed Discontinued |
